Original Article

You have full text access to this OnlineOpen article

Efficacy and safety of neoadjuvant trastuzumab combined with paclitaxel and epirubicin

A retrospective review of the M. D. Anderson experience

  1. Shaheenah Dawood MBBCh, MRCP1,2,
  2. Ana M. Gonzalez-Angulo MD1,
  3. Florentia Peintinger MD3,
  4. Kristine Broglio MS4,
  5. William F. Symmans MD3,
  6. Shu-Wan Kau MD1,
  7. Rabiul Islam MD1,
  8. Gabriel N. Hortobagyi MD1,
  9. Aman U. Buzdar MD1,†,*

Article first published online: 23 JUL 2007

DOI: 10.1002/cncr.22895

Issue

Cancer

Cancer

Volume 110, Issue 6, pages 1195–1200, 15 September 2007

Additional Information

How to Cite

Dawood, S., Gonzalez-Angulo, A. M., Peintinger, F., Broglio, K., Symmans, W. F., Kau, S.-W., Islam, R., Hortobagyi, G. N. and Buzdar, A. U. (2007), Efficacy and safety of neoadjuvant trastuzumab combined with paclitaxel and epirubicin. Cancer, 110: 1195–1200. doi: 10.1002/cncr.22895

Author Information

  1. 1

    Department of Breast Medical Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas

  2. 2

    Department of Medical Oncology, Department of Health and Medical Services, Dubai Hospital, Dubai, United Arab Emirates

  3. 3

    Department of Pathology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas

  4. 4

    Department of Quantitative Sciences, The University of Texas M. D. Anderson Cancer Center, Houston, Texas

  1. †

    Fax: (713) 383-0234

*Department of Breast Medical Oncology, The University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Blvd., Houston, TX 77030

Publication History

  1. Issue published online: 31 AUG 2007
  2. Article first published online: 23 JUL 2007
  3. Manuscript Accepted: 7 MAY 2007
  4. Manuscript Revised: 1 MAY 2007
  5. Manuscript Received: 21 MAR 2007

Funded by

  • Susan G. Komen Foundation
  • Nellie B. Connally Fund for Breast Cancer Research

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (114K)

REFERENCES

  • 1
    Early Breast Cancer Trialists' Collaborative Group. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomized trials. Lancet. 2005; 365: 1687–1717.
  • 2
    Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2006. CA Cancer J Clin. 2006; 56: 106–130.
    Direct Link:
  • 3
    Slamon DJ, Leyland-Jones B, Shak S, et al. Human breast cancer: use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpress HER2. N Engl J Med. 2001; 344: 783–792.
  • 4
    Piccart-Gebhart MJ, Procter M, Leyland-Jones B, et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med. 2005; 353: 1659–1684.
  • 5
    Romond EH, Perez EA, Bryant J, et al. Trastuzumab plus adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med. 2005; 353: 1673–1684.
  • 6
    Slamon D, Eiermann W, Robert N, et al. Phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel (ACT) with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab (ACTH) with docetaxel, carboplatin and trastuzumab (TCH) in her2 positive early breast cancer patients: BCIRG 006 study. Breast Cancer Res Treat. 2005; 94( suppl 1): S5.
  • 7
    Joensuu H, Kellokumpu-Lehtinen P-L, Bono P, et al. Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. N Engl J Med. 2006; 354: 809–820.
  • 8
    Kuerer HM, Newman LA, Smith TL, et al. Clinical course of breast cancer patients with complete pathological primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy. J Clin Oncol. 1999; 17: 460–469.
  • 9
    Buzdar AU, Ibrahim NK, Francis D, et al. Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth receptor 2-positive operable breast cancer. J Clin Oncol. 2005; 23: 3676–3685.
  • 10
    Buzdar AU, Valero V, Ibrahim N, et al. Prospective data of additional patients treated with neoadjuvant therapy with paclitaxel followed by FEC chemotherapy with trastuzumab in HER-2 positive breast cancer, and an update of initial study population. Breast Cancer Res Treat. 2005; 94( suppl 1): S223a.
  • 11
    Symmans W, Peintinger F, Hatzis C, et al. A new measurement of residual cancer burden to predict survival after neoadjuvant chemotherapy. J Clin Oncol. 2006 ASCO Annual Meeting Proceedings Part I. Vol 24, No. 18S (June 20 suppl), 2006: 536.
  • 12
    Hurley J, Doliny P, Reis I, et al. Docetaxel, cisplatin, and trastuzumab as primary systemic therapy for human epidermal growth factor receptor 2-postive locally advanced breast cancer. J Clin Oncol. 2006; 24: 1831–1838.
  • 13
    Burstein HJ, Harris LN, Gelman R, et al. Preoperative therapy with trastuzumab and paclitaxel followed by sequential adjuvant doxorubicin/cyclophosphomide for HER2 overexpressing stage II or III breast cancer: a pilot study. J Clin Oncol. 2003; 21: 46–53.
  • 14
    Harris LN, Burstein HJ, Gelman R, et al. Preoperative trastuzumab and vinorelbine (HN) is a highly active, well-tolerated regimen for HER2 3+/FISH + stage II/III breast cancer [abstract]. Proc Am Soc Clin Oncol. 2003; 22: 22. Abstract 86.
  • 15
    Green MC, Buzdar AU, Smith T, et al. Weekly paclitaxel improves pathological complete remission in operable breast cancer when compared with paclitaxel once every 3 weeks. J Clin Oncol. 2005; 23: 5983–5992.
  • 16
    Wolmark N, Wang J, Mamounas E, et al. Preoperative chemotherapy in patients with operable breast cancer: nine-year results from National Surgical Adjuvant Breast and Bowel Project B-18. J Natl Cancer Inst Monogr. 2001; 30: 96–102.
  • 17
    Lee YJ, Doliny P, Gomez-Fernandez C, et al. Docetaxel and cisplatin as primary chemotherapy treatment of locally advanced breast cancer. Clin Breast Cancer. 2004; 5: 371–376.
  • 18
    Escobar PF, Patrick RJ, Rybicki LA, et al. Prognostic significance of residual breast disease and axillary node involvement for patients who had primary induction chemotherapy for advanced breast cancer. Ann Surg Oncol. 2006; 13: 783–787.
  • 19
    Esteva FJ, Anderson K, Lin F, et al. Pharmacogenomic analysis of HER2 amplified breast cancer treated with preoperative trastuzumab and paclitaxel, 5-fluorouracil, epirubicin, cyclophosphamide (T/FEC) chemotherapy [abstract]. Proc ASCO 2006; 24(18S): 14S. Abstract 545.
  • 20
    Sledge GW, O'Neill A, Thor A, et al. Adjuvant trastuzumab: long term results of E2198 [abstract]. Breast Cancer Res Treat. 2006( suppl 1): S106. Abstract 2075.
View Full Article (HTML) Get PDF (114K)